Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
Amgen Inc
Antag Therapeutics ApS
Bain Biotech ApS
Carmot Therapeutics Inc
D&D Pharmatech Co Ltd
Eli Lilly and Co
Great Bay Bio Holdings Ltd
Hanmi Pharmaceuticals Co Ltd
Kariya Pharmaceuticals IVS
Longevity Biotech Inc
Novo Nordisk AS
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
(semaglutide + GIP alogue) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize GLP-1R, GIPR and GLR for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAJC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DD-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10624 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-6030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3437943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3493269 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3537021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize GIPR for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Peptide to Activate GIPR for Type I Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 to Agonize GIPR and GLP1R for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 to Agonize GIPR for Alzheimer’s Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize GIPR and GLP1R for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestil and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirzepatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-6590 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
Featured News & Press Releases
Jun 29, 2021: Latest data from SURPASS trials demonstrate Tirzepatide provided meaningful blood sugar reductions and weight loss
Jun 26, 2021: Lilly’s SURPASS-1 results published in The Lancet show tirzepatide’s superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
Jun 25, 2021: Lilly’s SURPASS-2 results published in The New England Jourl of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
Jun 11, 2021: Lilly announces webcast to provide diabetes portfolio update at ADA
May 21, 2021: Lilly’s tirzepatide meets endpoints in type 2 diabetes trial
May 04, 2021: Carmot Therapeutics announces investigatiol new drug (IND) clearance for CT-868, a dual GLP-1 and GIP receptor modulator for the treatment of overweight and obese patients with type 2 diabetes
Mar 05, 2021: Lilly’s tirzepatide leads to body weight reductions in type 2 diabetes trial
Feb 17, 2021: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly’s SURPASS program
Feb 17, 2021: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly’s SURPASS program
Dec 14, 2020: Lilly’s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
Dec 10, 2020: Lilly reports positive data from trial of tirzepatide for type 2 diabetes
Nov 11, 2020: Lilly announces webcast to provide an overview of Tirzepatide Phase 3 clinical program
Jul 22, 2020: FDA grants fast track desigtion for Hanmi LAPSTriple agonist
Jun 10, 2020: Lilly begins dosing in cardiovascular outcomes trial of tirzepatide
Mar 11, 2020: Hanmi’s SH treatment wins more orphan drug status
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Antag Therapeutics ApS, 2021
Pipeline by Bainan Biotech ApS, 2021
Pipeline by Carmot Therapeutics Inc, 2021
Pipeline by D&D Pharmatech Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Great Bay Bio Holdings Ltd, 2021
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Pipeline by Kariya Pharmaceuticals IVS, 2021
Pipeline by Longevity Biotech Inc, 2021
Pipeline by Novo Nordisk AS, 2021
Pipeline by Zealand Pharma AS, 2021
Pipeline by Zhejiang Doer Biologics Corp, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021